The Severity of Depressive Symptoms as an Independent Predictor of Sustained Virological Response During Treatment of Hepatitis C With Pegylated Interferon-α2a and Oral Ribavirin.

IF 2.9 3区医学 Q2 PSYCHIATRY

Psychosomatic Medicine Pub Date : 2024-02-01 Epub Date: 2024-01-08 DOI:10.1097/PSY.0000000000001274

Tomasz Pawłowski, Marek Radkowski, Karol Perlejewski, Tomasz Laskus, Krzysztof Małyszczak

{"title":"The Severity of Depressive Symptoms as an Independent Predictor of Sustained Virological Response During Treatment of Hepatitis C With Pegylated Interferon-α2a and Oral Ribavirin.","authors":"Tomasz Pawłowski, Marek Radkowski, Karol Perlejewski, Tomasz Laskus, Krzysztof Małyszczak","doi":"10.1097/PSY.0000000000001274","DOIUrl":null,"url":null,"abstract":"Background: Sustained virological response (SVR) is the best indicator of successful therapy for hepatitis C virus (HCV) infection. Patients with chronic HCV infection treated with pegylated interferon-α and ribavirin (PEG-IFN-α/RBV) can achieve SVR 56% of the time.Objectives: This study aimed to evaluate baseline predictors of SVR in patients treated with PEG-IFN-α/RBV for HCV chronic infection.Methods: A total of 101 patients receiving PEG-IFN-α/RBV for chronic HCV infection participated in the prospective cohort study. Symptoms of depression were assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS) before the treatment. The multivariate regression analysis was applied to determine predictors of SVR.Results: Of a total of 101 patients included, 99 patients reached the primary end point-24 weeks after completing treatment. After the initial analysis of probable predictive variables, the logistic analysis included age, sex, HCV genetic type, and MADRS score. The HCV genotype (odds ratio = 0.22 [confidence interval = 0.073-0.68, p = .008) and MADRS score (OR = 0.88 [confidence interval = 0.80-0.98), p = .013]) predicted an SVR outcome.Conclusions: The severity of depressive symptoms before treatment and HCV genotype are independent predictors of SVR.","PeriodicalId":20918,"journal":{"name":"Psychosomatic Medicine","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychosomatic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PSY.0000000000001274","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sustained virological response (SVR) is the best indicator of successful therapy for hepatitis C virus (HCV) infection. Patients with chronic HCV infection treated with pegylated interferon-α and ribavirin (PEG-IFN-α/RBV) can achieve SVR 56% of the time.

Objectives: This study aimed to evaluate baseline predictors of SVR in patients treated with PEG-IFN-α/RBV for HCV chronic infection.

Methods: A total of 101 patients receiving PEG-IFN-α/RBV for chronic HCV infection participated in the prospective cohort study. Symptoms of depression were assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS) before the treatment. The multivariate regression analysis was applied to determine predictors of SVR.

Results: Of a total of 101 patients included, 99 patients reached the primary end point-24 weeks after completing treatment. After the initial analysis of probable predictive variables, the logistic analysis included age, sex, HCV genetic type, and MADRS score. The HCV genotype (odds ratio = 0.22 [confidence interval = 0.073-0.68, p = .008) and MADRS score (OR = 0.88 [confidence interval = 0.80-0.98), p = .013]) predicted an SVR outcome.

Conclusions: The severity of depressive symptoms before treatment and HCV genotype are independent predictors of SVR.

查看原文本刊更多论文

在使用聚乙二醇干扰素-α2a 和口服利巴韦林治疗丙型肝炎期间，抑郁症状的严重程度是持续病毒学应答的独立预测因素。

目的：持续病毒学应答（SVR持续病毒学应答（SVR）是丙型肝炎病毒（HCV）感染治疗成功的最佳指标。接受聚乙二醇干扰素-α和利巴韦林（PEG-IFN-α /RBV）治疗的慢性丙型肝炎病毒感染患者在56%的情况下可获得SVR。评估接受 PEG-IFN-α /RBV 治疗的 HCV 慢性感染患者 SVR 的基线预测因素：共有101名接受PEG-IFN-α/RBV治疗的慢性HCV感染患者参与了前瞻性队列研究。治疗前使用蒙哥马利-阿斯伯格抑郁量表（MADRS）评估抑郁症状。采用多变量回归分析确定 SVR 的预测因素：在纳入的 101 名患者中，99 名患者在完成治疗 24 周后达到了主要终点。在对可能的预测变量进行初步分析后，逻辑分析包括：年龄、性别、HCV 基因类型、MADRS 评分。HCV基因型OR=0.22（CI 0.073 - 0.68，p=0.008）和MADRS评分OR=0.88（CI 0.80 - 0.98），p=0.013）预测了SVR结果：结论：治疗前抑郁症状的严重程度和 HCV 基因型是 SVR 的独立预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psychosomatic Medicine 医学-精神病学

CiteScore

5.10

自引率

0.00%

发文量

258

审稿时长

4-8 weeks

期刊介绍： Psychosomatic Medicine is the official peer-reviewed journal of the American Psychosomatic Society. The journal publishes experimental, clinical, and epidemiological studies on the role of psychological and social factors in the biological and behavioral processes relevant to health and disease. Psychosomatic Medicine is an interdisciplinary peer-reviewed journal devoted to high-quality science on biobehavioral mechanisms, brain-behavior interactions relevant to physical and mental disorders, as well as interventions in clinical and public health settings. Psychosomatic Medicine was founded in 1939 and publishes interdisciplinary research articles relevant to medicine, psychiatry, psychology, and other health-related disciplines. The print journal is published nine times a year; most articles are published online ahead of print. Supplementary issues may contain reports of conferences at which original research was presented in areas relevant to the psychosomatic and behavioral medicine.